Phase 1: 95, Phase 2: 147, Phase 3: 232, Other: 239
AstraZeneca operates one of the broadest oncology pipelines in the industry, with particular depth in lung cancer (Tagrisso/osimertinib and successors), ovarian and breast cancer (Lynparza/olaparib), and immuno-oncology (Imfinzi/durvalumab). The AstraZeneca/Daiichi-Sankyo collaboration on antibody-drug conjugates — including Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan — has reshaped the ADC landscape across HER2-expressing tumors. Outside oncology, AstraZeneca's CVRM franchise (Farxiga/dapagliflozin, Brilinta/ticagrelor) continues expanding indications into heart failure and chronic kidney disease.
- Oncology
- Lung cancer (EGFR/ALK/HER2)
- Ovarian cancer
- Breast cancer ADCs
- Cardiovascular / Metabolic
- Rare disease
- Tagrisso (osimertinib) — EGFR-mutant NSCLC
- Lynparza (olaparib) — BRCA-mutated cancers
- Imfinzi (durvalumab) — PD-L1 checkpoint
- Enhertu (trastuzumab deruxtecan) — HER2 ADC
- Dato-DXd (datopotamab deruxtecan) — TROP2 ADC
- Calquence (acalabrutinib) — B-cell malignancies
Monitor the AstraZeneca pipeline daily
Get alerts when AstraZeneca registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Trials |
|---|---|
| Asthma | 35 |
| Breast Cancer | 29 |
| Healthy Participants | 24 |
| Non-Small Cell Lung Cancer | 18 |
| Non-small Cell Lung Cancer | 18 |
| Ovarian Cancer | 16 |
| Systemic Lupus Erythematosus | 16 |
| Hepatocellular Carcinoma | 14 |
AstraZeneca registers new combination trials for its ADC portfolio monthly. Monitoring their pipeline helps identify new competitive entries into HER2, TROP2, and EGFR-targeted spaces before they appear in analyst reports.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to AstraZeneca's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: AstraZeneca may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your AstraZeneca pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia NCT06137118 | Recruiting | Completion pushed: 2027-06-29 → 2028-09-15 | 2026-08-20 |
| A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs… NCT07000149 | Active, Not Recruiting | Completion moved earlier: 2032-07-29 → 2027-01-29 | 2026-08-04 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants… NCT07681596 | Recruiting | Completion pushed: 2029-10-30 → 2031-03-06 | 2026-08-28 |
| NIS to Examine the Effectiveness of TDC in Patients With Metastatic… NCT06494540 | Recruiting | Completion pushed: 2028-06-30 → 2029-12-31 | 2026-08-21 |
| A Study of Novel Agents or Combinations as Perioperative Treatment in… NCT07069712 | Recruiting | Completion pushed: 2028-09-06 → 2029-07-16 | 2026-08-18 |
Each trial page shows every change DataLookout has recorded for that trial.